Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omaveloxolone TQT Study in Healthy Subjects
NCT05927649Phase 1Completed
- Sponsor
- Biogen
- Start
- Jul 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of omaveloxolone in Friedreich's ataxia (FA) (6 arms), sponsored by Biogen. Primary endpoint: Change from baseline in placebo-corrected QTcF at Day 1. Started Jul 2023; status: completed.
02
Drugs
omaveloxolone
03
Conditions
Friedreich's ataxia (FA)
Beyond the preview
Go deeper on NCT05927649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05927649.